Role of the melatonin system in the control of sleep: therapeutic implications.

abstract：:gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

journal_title：CNS drugs

authors： Czuczwar SJ,Patsalos PN

更新日期：2001-01-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...

journal_title：CNS drugs

authors： Childress AC,Sallee FR

更新日期：2014-02-01 00:00:00

abstract：:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

journal_title：CNS drugs

authors： Cather C,Pachas GN,Cieslak KM,Evins AE

更新日期：2017-06-01 00:00:00

abstract：:Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...

journal_title：CNS drugs

authors： Lyseng-Williamson KA

更新日期：2011-10-01 00:00:00

abstract：:Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...

journal_title：CNS drugs

authors： Keating GM,Lyseng-Williamson KA

更新日期：2010-09-01 00:00:00

abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

journal_title：CNS drugs

authors： Deeks ED,Keating GM

更新日期：2010-01-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：CNS drugs

authors： Chidambaran V,Costandi A,D'Mello A

更新日期：2018-09-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00

abstract：:Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

journal_title：CNS drugs

authors： Deisenhammer F

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

journal_title：CNS drugs

authors： Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

更新日期：2020-02-01 00:00:00

abstract：:Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

journal_title：CNS drugs

authors： Scott LJ

更新日期：2011-08-01 00:00:00

abstract：:In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

journal_title：CNS drugs

authors： Foster TC

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

journal_title：CNS drugs

authors： Dodick DW,Sandrini G,Williams P

更新日期：2007-01-01 00:00:00

abstract：:L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...

journal_title：CNS drugs

authors： Schaeffer E,Pilotto A,Berg D

更新日期：2014-12-01 00:00:00

abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...

journal_title：CNS drugs

authors： Abudy A,Juven-Wetzler A,Zohar J

更新日期：2011-07-01 00:00:00

abstract：:Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...

journal_title：CNS drugs

authors： Bagert B,Camplair P,Bourdette D

更新日期：2002-01-01 00:00:00

abstract：:Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2018-07-01 00:00:00

abstract：:The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

journal_title：CNS drugs

authors： Tarakad A,Jimenez-Shahed J

更新日期：2018-12-01 00:00:00

abstract：:The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...

journal_title：CNS drugs

authors： Erhardt S,Olsson SK,Engberg G

更新日期：2009-01-01 00:00:00

abstract：:Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...

journal_title：CNS drugs

authors： Kacperski J,Hershey AD

更新日期：2016-09-01 00:00:00

abstract：SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

journal_title：CNS drugs

authors： Davis R,Wilde MI

更新日期：1996-05-01 00:00:00

abstract：BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

journal_title：CNS drugs

authors： Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

journal_title：CNS drugs

authors： Sutter R,Marsch S,Rüegg S

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

journal_title：CNS drugs

authors： Tobinick E

更新日期：2011-02-01 00:00:00

abstract：:Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

journal_title：CNS drugs

authors： Warnock JJ

更新日期：2002-01-01 00:00:00

abstract：:Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

journal_title：CNS drugs

authors： Logallo N,Kvistad CE,Nacu A,Thomassen L

更新日期：2016-02-01 00:00:00

abstract：UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

journal_title：CNS drugs

authors： Wagstaff AJ,Ormrod D,Spencer CM

更新日期：2001-01-01 00:00:00

abstract：:Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

journal_title：CNS drugs

authors： Barateau L,Lopez R,Dauvilliers Y

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

journal_title：CNS drugs

authors： Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

更新日期：2012-10-01 00:00:00

abstract：:Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and lon...

journal_title：CNS drugs

authors： Frampton JE,Plosker GL

更新日期：2007-01-01 00:00:00